MannKind says partnership deal could come 'days or months' after PDUFA MannKind CFO Matthew Pfeffer repeated that the company is in talks with potential commercialization partners for Afrezza, but says its "hard to say" how long after Afrezza's PDUFA date that a partnership deal could be announced. Pfeffer said an announcement could come "days" after the PDUFA or it could take "months." Pfeffer says at least one partner it is talking with is discussing "more of a profit sharing arrangement" than a licensing deal. MannKind CFO Matthew Pfeffer is speaking at the Wells Fargo Healthcare conference.
MannKind triples production capacity for Afrezza MannKind announced that it has completed the validation of two additional filling lines for the manufacture of Afrezza inhalation powder. Material produced during the validation runs, including the recently approved 12 unit cartridges, will be supplied to Sanofi to support the launch of the new dosage strength, which is expected later this quarter.